Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Dose-escalation Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IVB102 Injection in Subjects With X-linked Retinoschisis (XLRS)

NCT06289452 is registered in ClinicalTrials.gov with InnoVec Biotherapeutics Inc. as lead sponsor.

NCT NCT06289452
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06289452 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Dose-escalation Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IVB102 Injection in Subjects With X-linked Retinoschisis (XLRS)
Lead sponsor
InnoVec Biotherapeutics Inc.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
March 8, 2024
Completion date
December 31, 2029
Enrollment
18 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

eye diseases, retinal degeneration, retinal disease, retinoschisis